These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 27140204)

  • 21. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
    Wang C; Xiong B; Cai L
    BMC Cardiovasc Disord; 2017 Jun; 17(1):164. PubMed ID: 28633650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial.
    Sarma S; Mentz RJ; Kwasny MJ; Fought AJ; Huffman M; Subacius H; Nodari S; Konstam M; Swedberg K; Maggioni AP; Zannad F; Bonow RO; Gheorghiade M;
    Eur J Heart Fail; 2013 Feb; 15(2):194-202. PubMed ID: 23059198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
    J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
    Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
    J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
    Shen L; Ramires F; Martinez F; Bodanese LC; Echeverría LE; Gómez EA; Abraham WT; Dickstein K; Køber L; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Jhund PS; Gimpelewicz CR; McMurray JJV;
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M;
    Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
    Ter Maaten JM; Valente MA; Damman K; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Bloomfield DM; Cotter G; Davison B; Subacius H; van Veldhuisen DJ; van der Meer P; Hillege HL; Gheorghiade M; Voors AA
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27266853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
    Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
    J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.
    Ambrosy AP; Cerbin LP; Armstrong PW; Butler J; Coles A; DeVore AD; Dunlap ME; Ezekowitz JA; Felker GM; Fudim M; Greene SJ; Hernandez AF; O'Connor CM; Schulte P; Starling RC; Teerlink JR; Voors AA; Mentz RJ
    JACC Heart Fail; 2017 Jan; 5(1):1-13. PubMed ID: 28034373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.
    Vaduganathan M; Goldsmith SR; Senni M; Butler J; Gheorghiade M
    Eur J Heart Fail; 2016 Feb; 18(2):185-91. PubMed ID: 26443242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
    Gheorghiade M; Pang PS; Ambrosy AP; Lan G; Schmidt P; Filippatos G; Konstam M; Swedberg K; Cook T; Traver B; Maggioni A; Burnett J; Grinfeld L; Udelson J; Zannad F
    Heart Fail Rev; 2012 May; 17(3):485-509. PubMed ID: 21932146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.
    Upshaw JN; Konstam MA; Klaveren Dv; Noubary F; Huggins GS; Kent DM
    Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27514751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
    Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
    Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).
    Vaduganathan M; Patel RB; Mentz RJ; Subacius H; Chatterjee NA; Greene SJ; Ambrosy AP; Maggioni AP; Udelson JE; Swedberg K; Konstam MA; O'Connor CM; Butler J; Gheorghiade M; Zannad F
    Am J Cardiol; 2018 Jul; 122(2):255-260. PubMed ID: 29731121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M;
    Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
    Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Nanayakkara S; Byrne M; Mak V; Carter K; Dean E; Kaye DM
    J Am Heart Assoc; 2020 Jul; 9(13):e015026. PubMed ID: 32552264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.